Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Integrated DNA Technologies Launches its First Cancer Panel

Published: Friday, October 25, 2013
Last Updated: Friday, October 25, 2013
Bookmark and Share
Fast and accurate screening for mutations identified in acute myeloid lymphoma using the xGen® Acute Myeloid Lymphoma Panel v1.0.

Integrated DNA Technologies (IDT) is enabling cancer research with its latest next generation sequencing (NGS) product, the xGen® Acute Myeloid Leukemia Cancer Panel v1.0.

Consisting of 11,743 xGen Lockdown® Probes, this cancer panel targets over 260 clinically relevant genes that were found to be mutated in a study of 200 patients with acute myeloid leukemia (AML), and published by The Cancer Genome Atlas consortium.

The AML Cancer Panel is used for enriching the genome for regions of interest before performing NGS. It can, therefore, be used to study disease occurrence and progression, and help with the development of better targeted therapies.

Target enrichment enables users to focus their sequencing efforts on specific regions of the genome, providing a cost-effective and reliable alternative to whole genome sequencing, making NGS more accessible to researchers.

By including only relevant xGen Lockdown Probes, the AML Cancer Panel enables high coverage of targeted regions, with minimal GC bias.

As cancer is a genetic disease driven by both heritable and somatic mutations, NGS technologies can significantly improve its detection, management, and treatment.

DNA from a patient could be enriched for these AML-related genes using capture panels such as the xGen AML Cancer Panel and sequenced to identify mutated genes. Subsequently, the patient would receive therapy specific to their cancer profile.

Periodic sequencing of these genes would allow monitoring of disease progression for both research and clinical purposes. As such, more tailored therapies can be developed and a personalized treatment regimen can be implemented.

Ibrahim Jivanjee, Product Manager for NGS at IDT, commented, “We have invested a significant amount of resources into the development of our xGen product line, and are delighted to see such success from these products already. The launch of our first cancer panel has been a significant milestone, with early collaborators demonstrating its potential for use in patient diagnosis and monitoring.”

He continued, “With next gen sequencing becoming an increasingly prominent technique within cancer diagnosis and personalized medicine, IDT, with its leading position in oligonucleotide technology will continue to be at the forefront of developments in this rapidly advancing field.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

TBUSA, IDT Announce Collaboration
Collaboration aims to support targeted RNA Sequencing.
Wednesday, April 27, 2016
IDT Acquires AITbiotech
Acquisition increases capacity to deliver high quality, locally manufactured oligos .
Thursday, December 10, 2015
Discover the Latest NGS-Based Assays Guiding Precision Oncology
IDT joins forces with Foundation Medicine in AMP workshop.
Saturday, November 08, 2014
IDT Acquires SURVEYOR® Nuclease Business from Transgenomic
Addition of SURVEYOR enzyme and kits expands IDT's molecular biology product offerings.
Wednesday, July 02, 2014
Providing a Rapid and Reliable Method of Gene Cloning
Integrated DNA Technologies will be speaking at the upcoming Antibody Engineering and Therapeutics conference.
Monday, December 02, 2013
Webinar: the Cutting-edge qPCR Approach to Single-cell Expression Profiling
Join IDT and Professor Mikael Kubista for insight into pioneering qPCR methods, June 25.
Monday, June 24, 2013
IDT Launches Michael Zuker’s UNAFold Page
UNAFold secondary structure prediction software to be used to accurately detect secondary structures within sequences submitted by customers.
Thursday, December 02, 2010
IDT Presents at Presidential Commission for the Study of Bioethical Issues
Representing the International Gene Synthesis Consortium and its ongoing work to prevent the misuse of synthetic genes.
Tuesday, September 21, 2010
IDT is Awarded Further Funding for Gene Silencing Research
Company receives a Phase II SIBR grant to fund the ongoing ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Thursday, July 22, 2010
IDT Earns ISO 9001:2008 Certification at its European Oligonucleotide Production Headquarters
Worldwide certification of quality systems at all manufacturing operations completed.
Tuesday, April 27, 2010
Integrated DNA Technologies and Glycon Partner in Australia
Glycon will offer Australia’s scientists local sales and technical support of IDT’s products, complementing IDT’s existing global customer care network.
Monday, April 19, 2010
IDT Secures Funding for new Gene Silencing Research
IDT has been awarded $99,750 from NIH to continue work on its ‘Gene Silencing with U1 Adapter Oligonucleotides’ research project.
Monday, September 07, 2009
Major International Conferences to Hear About the Risks and Rewards of Synthetic Biology
IDT will be presenting recent developments in RNAi research, at Analytica and the RNAi World Congress.
Wednesday, March 19, 2008
IDT Acquires Belgian Manufacturer RNA-TEC
Purchase expands IDT's large-scale RNA synthesis capabilities; builds presence in European markets.
Tuesday, September 19, 2006
Scientific News
Revealing the Genetic Causes of Bowel Cancer
A landmark study has given the most detailed picture yet of the genetics of bowel cancer — the UK's fourth most common cancer.
Self-Assembling Protein Shell for Drug Delivery
Made-to-order nano-cages open possibilities of shipping cargo into living cells or fashioning small chemical reactors.
Fighting Resistant Blood Cancer Cells
Biologists present new findings on chronic myeloid leukemia and possible therapeutic approaches.
Tumor Cells Develop Predictable Characteristics
Scientists have discovered that cancer cells at the edge of a tumor that are close to the surrounding environment are predictably different from the cells within the interior of the tumor.
Guided Chemotherapy Missiles
Latching chemotherapy drugs onto proteins that seek out tumors could provide a new way of treating tumors in the brain or with limited blood supply that are hard to reach with traditional chemotherapy.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Biomarkers That Could Help Give Cancer Patients Better Survival Estimates Discovered
UCLA research may also help scientists suppress dangerous genetic sequences.
Body’s Own Gene Editing System Generates Leukemia Stem Cells
Inhibiting the editing enzyme may provide a new therapeutic approach for blood cancers.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!